1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
633A6DF2FDCD871A265257F7900252773
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-priority-review-vouchers-innovative-approach-accelerate-new-product-reviews-fda-encourage-development-medicines-neglected-diseases?opendocument
18
19opendocument
2054.198.246.164
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services New Product Development New Product Planning

Priority Review Vouchers: An Innovative Approach To Accelerate New Product Reviews by the FDA and Encourage Development of Medicines For Neglected Diseases

ID: 5406


Features:

20 Info Graphics

3 Data Graphics

38 Metrics

4 Narratives


Pages/Slides: 35


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from " Priority Review Vouchers: An Innovative Approach To Accelerate New Product Reviews by the FDA and Encourage Development of Medicines For Neglected Diseases"

STUDY OVERVIEW

Proposed by three Duke University professors in a 2006 Health Affairs academic paper, the FDA's priority review voucher was written into law in 2007. Under this law, developers of medicines for specified neglected or rare pediatric diseases receive a voucher for six-month priority review from the FDA to be redeemed with another product of choice or sold to another organization.

However, certain restrictions like the sunset clause have raised uncertainties around the value of priority review vouchers among biopharmaceutical companies. Moreover, for companies that are unsuccessful in their use of a priority review voucher, the cost of failure can be particularly high due to the cost to procure and use the voucher.

This study provides a brief overview of priority review vouchers, its benefits, recent developments and criticisms against the voucher program.

KEY TOPICS

  • History of Priority Review Vouchers
  • Working Benefits of Priority Review Vouchers
  • Priority Review Vouchers are Benefiting Companies
  • Recent Developments & Critics Against Priority Review Vouchers
  • What Does the Future Hold?

KEY METRICS

  • Number of approved orphan products by year
  • Prices paid by priority review voucher buyers in millions

METHODOLOGY

This study was created using multiple secondary research sources.


Industries Profiled:
Consulting; Biotech; Medical Device; Pharmaceutical; Diagnostic; Clinical Research


Companies Profiled:
Pharma; Biotech; Medical Device Companies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.